Neuraly and Enigma Biomedical USA announce research license and commercialization option agreement for PET imaging biomarker, PMI04
- Neuraly and Enigma Biomedical USA have signed an agreement for PMI04, a PET imaging biomarker for neuroinflammation.
- Enigma gains an exclusive research license and an option for commercialization rights based on research outcomes.
- PMI04 targets CSF-1R in activated microglia, aiding in diagnosing neurodegenerative diseases like Alzheimer's and Parkinson's.
- Upon successful research, Enigma will receive exclusive commercialization rights, with Neuraly receiving upfront and milestone payments.
Read more
Enigma Biomedical USA partners with University of Wisconsin–Madison for neurodegenerative disease research
- Enigma Biomedical USA and UW–Madison have formed a partnership to develop next-generation PET imaging and fluid biomarkers.
- The collaboration will focus on advancing research in neurodegenerative diseases at the new Biomarker Development Lab.
- Key scientists involved include Hartmuth Kolb, Sterling Johnson, Henrik Zetterberg, and Bradley Christian.
- The partnership includes option agreements for Enigma to license technology developed through the collaboration.
Read more
